Inventor · disambiguated record
Simon Holton
Also filed as: HOLTON SIMON
17 granted patents·18 pending applications·24 citations·filing 2010–2023
89Inventor score
Top patents by PatentIndex Score
35 records- 0185US10584167B2Anti-CEACAM6 antibodies and uses thereofBayer Pharma AG·Filed 2016·Granted Mar 10, 2020·4 cites·16 claims
- 0279US11866495B2Anti-CEACAM6 antibodies and uses thereofDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2020·Granted Jan 9, 2024·1 cites·20 claims
- 0378US10266548B2Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseasesBAYER IP GMBH·Filed 2017·Granted Apr 23, 2019·2 cites·2 claims
- 0478US9643953B2Substituted benzylpyrazolesBAYER IP GMBH·Filed 2012·Granted May 9, 2017·5 cites·10 claims
- 0577US9682974B2Heteroaryl substituted pyrazolesBayer Pharma AG·Filed 2014·Granted Jun 20, 2017·4 cites·8 claims
- 0675US9745285B2Heteroaryl substituted pyrazolesBayer Pharma AG·Filed 2014·Granted Aug 29, 2017·3 cites·5 claims
- 0774US9765058B2Substituted benzylpyrazolesBayer Pharma AG·Filed 2014·Granted Sep 19, 2017·3 cites·14 claims
- 0871US12503491B2MASP inhibitory compounds and uses thereofBAYER AG·Filed 2023·Granted Dec 23, 2025·0 cites·8 claims
- 0966US10350206B2Benzyl substituted indazoles as BUB1 inhibitorsBayer Pharma AG·Filed 2015·Granted Jul 16, 2019·1 cites·28 claims
- 1064US10604532B2Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseasesBAYER IP GMBH·Filed 2019·Granted Mar 31, 2020·0 cites·6 claims
- 1163US8551980B2Substituted triazolopyridinesSCHULZE VOLKER·Filed 2010·Granted Oct 8, 2013·1 cites·13 claims
- 1262US11667675B2MASP inhibitory compounds and uses thereofBAYER AG·Filed 2020·Granted Jun 6, 2023·0 cites·3 claims
- 1362US2024150277A1Covalent PPARG inverse-agonistsBAYER AG·Filed 2023·Application pending·0 cites
- 1461US11773164B2Anti-CEACAM6 antibodies and uses thereofBayer Pharma AG·Filed 2020·Granted Oct 3, 2023·0 cites·20 claims
- 1561US2016046604A1Heteroaryl substituted indazolesBayer Pharma AG·Filed 2014·Application pending·0 cites
- 1659US2016052912A1Diaminoheteroaryl substituted indazolesBAYER PHARMA AKITIENGESELLSCHAFT·Filed 2014·Application pending·0 cites
- 1756US2023382904A1SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOFUNIV JOHNS HOPKINS·Filed 2021·Application pending·0 cites
- 1853US2017275267A1Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancerBayer Pharma AG·Filed 2017·Application pending·0 cites
- 1952US2014249133A1Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseasesBAYER IP GMBH·Filed 2012·Application pending·0 cites
- 2052US2024010684A1Masp inhibitory compounds and uses thereofBAYER AG·Filed 2021·Application pending·0 cites
- 2151US2016046610A13-heteroaryl substituted indazolesBayer Pharma AG·Filed 2014·Application pending·0 cites
- 2251US2017283396A1Diaminoheteroaryl substituted indazolesBayer Pharma AG·Filed 2017·Application pending·0 cites
- 2350US2023086702A1Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a]pyridine derivatives and use thereofUNIV JOHNS HOPKINS·Filed 2020·Application pending·0 cites
- 2448US2015141372A1Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancerBayer Pharma AG·Filed 2013·Application pending·0 cites
- 2547US2021017174A1Identification and use of erk5 inhibitorBAYER AG·Filed 2019·Application pending·0 cites
- 2645US2017275268A1Heteroaryl substituted indazolesBayer Pharma AG·Filed 2017·Application pending·0 cites
- 2744US2016145267A1Heteroaryl substituted pyrazolesBayer Pharma AG·Filed 2014·Application pending·0 cites
- 2844US2016168130A1Heteroaryl substituted pyrazolesBayer Pharma AG·Filed 2014·Application pending·0 cites
- 2942US2021047297A14-(3-amino-6-fluoro-1h-indazol-5-yl)-1,2,6-trimethyl-1,4-dihydropyridine-3,5-dic arbonitrile compounds for treating hyperproliferative disordersBayer Pharma AG·Filed 2019·Application pending·0 cites
- 3040US2018148418A1Amido-substituted cyclohexane derivativesBayer Pharma AG·Filed 2016·Application pending·0 cites
- 3135US2017305882A1Benzyl substituted indazoles as bub1 kinase inhibitorsBayer Pharma AG·Filed 2015·Application pending·0 cites
- 3234US9676766B2TriazolopyridinesSCHULZE VOLKER·Filed 2010·Granted Jun 13, 2017·0 cites·14 claims
- 3334US9555022B2Substituted triazolopyridinesSCHULZE VOLKER·Filed 2011·Granted Jan 31, 2017·0 cites·15 claims
- 3433US10428044B23-amino-1,5,6,7-tetrahydro-4H-indol-4-onesBayer Pharma AG·Filed 2015·Granted Oct 1, 2019·0 cites·13 claims
- 3530US9884063B2Amido-substituted azole compoundsBayer Pharma AG·Filed 2015·Granted Feb 6, 2018·0 cites·17 claims
Join the waitlist — get patent alerts
Get an alert when Simon Holton files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →